TCCL Archive
Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival
TCCL Archive
Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis
TCCL Archive
Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL
TCCL Archive
Biomarker May Predict Prostate Cancer Metastases
TCCL Archive
Individualized Cancer Vaccines Show 90% Survival at 6 Months
TCCL Archive
Dendritic Cell Vaccine Increases PFS in Phase II Clinical Trial
TCCL Archive
Two Phase II Studies of Ibrutinib Deliver High Response Rates
TCCL Archive
NLST Suggests 18.5 Percent Of LDCT-Detected Cancers Could Be Indolent
TCCL Archive
Study: BRCA2-Negative Women Could Still Have High Risk
TCCL Archive
Velcade Addition Can Improve Graft-Versus-Host Outcomes
TCCL Archive
NCI CTEP Approved Trials For the Month of December
TCCL Archive
FDA Expands Nexavar Indication To Include Thyroid Cancer
Trending Stories
- With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shutdown
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - Anthony Letai sworn in as 18th NCI director
- Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research
- Population-based cancer surveillance is a national treasure at risk
- Former NCI official’s nonprofit seeks to tell the stories of cancer patients
Patient Action for Cancer Research aims to show impact of federal research
